The Indiana University Cognitive Health Outcomes Investigation of the Comparative Effectiveness of dementia screening (CHOICE) study: study protocol for a randomized controlled trial

Nicole R Fowler, Amanda Harrawood, Amie Frame, Anthony J Perkins, Sujuan Gao, Christopher M Callahan, Greg A Sachs, Dustin D French, Malaz A Boustani, Nicole R Fowler, Amanda Harrawood, Amie Frame, Anthony J Perkins, Sujuan Gao, Christopher M Callahan, Greg A Sachs, Dustin D French, Malaz A Boustani

Abstract

Background: Dementia affects over 4 million people in the US and is frequently unrecognized and underdiagnosed in primary care. Routine dementia screening in primary care is not recommended by the US Preventive Services Task Force due to lack of empirical data on the benefits and harms of screening. This trial seeks to fill this gap and contribute information about the benefits, harms, and costs of routine screening for dementia in primary care.

Methods/design: Single-blinded, parallel, randomized controlled clinical trial with 1:1 allocation. A total of 4,000 individuals aged ≥65 years without a diagnosis of dementia, cognitive impairment, or serious mental illness receiving care at primary care practices within two cities in Indiana. Subjects will be randomized to either i) screening for dementia using the Memory Impairment Screen Telephone version or ii) no screening for dementia. Subjects who screen positive for dementia will be referred to the local Aging Brain Care program that delivers an evidence-based collaborative care model for dementia and depression. Research assistants will administer the 15-item Health Utility Index, Patient Health Questionnaire, Generalized Anxiety Disorder Scale, and Medical Outcomes Study at baseline, 1, 6, and 12 months. Information about advanced care planning will be collected at baseline and 12 months. All enrollees' medical records will be reviewed to collect data on health care utilization and costs.

Discussion: We have two primary hypotheses; first, in comparison to non-screened subjects, those who are screened and referred to a dementia collaborative care program will have a higher health-related quality of life as measured by the Health Utility Index at 12 months post-screening. Second, in comparison to non-screened subjects, those who are screened and referred to a dementia collaborative care program will not have higher depression or anxiety at one month post-screening as measured by the Patient Health Questionnaire and Generalized Anxiety Disorder Scale scales. Our secondary hypothesis is that screened subjects will have an Incremental Cost-Effectiveness Ratio below the maximum acceptable threshold of $60,000 per quality adjusted life year saved at 12 months.

Trial registration: Ongoing; registered on September 19, 2012. ClinicalTrials.gov Identifier: 2012 NCT01699503.

Figures

Figure 1
Figure 1
Study protocol flowchart.

References

    1. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–132. doi: 10.1159/000109998.
    1. Hebert LE, Scherr PA, Bienias JL, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–1122. doi: 10.1001/archneur.60.8.1119.
    1. Association A’s. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8(2):131–168.
    1. Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, Hui SL, Hendrie HC. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20(7):572–577. doi: 10.1007/s11606-005-0103-7.
    1. Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, McCarten JR, Morris JC, Salmon DP, Schmitt FA, Stefanacci RG, Mendiondo MS, Peschin S, Hall EJ, Fillit H, Ashford JW. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement. 2013;9(2):151–159. doi: 10.1016/j.jalz.2012.08.008.
    1. Ashford JW, Borson S, O’Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Henry Brodaty H, Schmitt FA, Kraemer HC, Buschke H, Fillit H. Should older adults be screened for dementia? It is important to screen for evidence of dementia! Alzheimers Dement. 2007;3(2):75–80. doi: 10.1016/j.jalz.2007.03.005.
    1. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. U.S. Preventive Services Task Force. Screening for dementia in primary care: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2003;138(11):927–937.
    1. Lin J, O’Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;159(9):601–612.
    1. Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, Thies W, Fried LB. Alzheimer’s Association recommendation for operationalizing the detection of cognitive impairment during the medicare annual wellness visit in a primary care setting. Alzheimers Dement. 2013;9(2):141–150. doi: 10.1016/j.jalz.2012.09.011.
    1. Boustani M, Sachs GA, Alder CA, Munger S, Schubert CC, Austrom MG, Hake A, Unverzagt FW, Farlow M, Matthews BR, Perkins AJ, Beck RA, Callahan CM. Implementing innovative models of dementia care: the healthy aging brain center. Aging Ment Health. 2011;15(1):13–22. doi: 10.1080/13607863.2010.496445.
    1. Callahan CM, Boustani MA, Weiner M, Beck RA, Livin LR, Kellams JJ, Willis DR, Hendrie HC. Implementing dementia care models in primary care settings: the aging brain care medical home. Aging Ment Health. 2011;15(1):5–12. doi: 10.1080/13607861003801052.
    1. Chan DC, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58(6):548–554. doi: 10.1093/gerona/58.6.M548.
    1. Counsell SR, Callahan CM, Buttar AB, Clark DO, Frank KI. Geriatric Resources for Assessment and Care of Elders (GRACE): a new model of primary care for low-income seniors. J Am Geriatr Soc. 2006;54(7):1136–1141. doi: 10.1111/j.1532-5415.2006.00791.x.
    1. Lipton RB, Katz MJ, Kuslansky G, Sliwinski MJ, Stewart WF, Verghese J, Crystal HA, Buschke H. Screening for dementia by telephone using the memory impairment screen. J Am Geriatr Soc. 2003;51(10):1382–1390. doi: 10.1046/j.1532-5415.2003.51455.x.
    1. Brodaty H, Low LF, Gibson L, Burns K. What is the best dementia screening instrument for general practitioners to use? Am J Geriatr Psychiatry. 2006;14(5):391–400. doi: 10.1097/01.JGP.0000216181.20416.b2.
    1. McCarten JR, Anderson P, Kuskowski MA, McPherson SE, Borson S, Dysken MW. Finding dementia in primary care: the results of a clinical demonstration project. J Am Geriatr Soc. 2012;60(2):210–217. doi: 10.1111/j.1532-5415.2011.03841.x.
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi: 10.1016/j.jalz.2011.03.005.
    1. Callahan CM, Boustani M, Unverzagt FW, Austrom MG, Damush TM, Perkins AJ, Fultz BA, Hui SL, Counsell SR, Hendrie HC. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295(18):2148–2157. doi: 10.1001/jama.295.18.2148.
    1. Austrom MG, Damush TM, Hartwell CW, Perkins A, Unverzagt F, Boustani M, Hendrie HC, Callahan CM. Development and implementation of nonpharmacologic protocols for the management of patients with Alzheimer’s disease and their families in a multiracial primary care setting. Gerontologist. 2004;44(4):548–553. doi: 10.1093/geront/44.4.548.
    1. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54. doi: 10.1186/1477-7525-1-54.
    1. Kavirajan H, Hays RD, Vassar S, Vickrey BG. Responsiveness and construct validity of the health utilities index in patients with dementia. Med Care. 2009;47(6):651–661. doi: 10.1097/MLR.0b013e31819241b9.
    1. Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE, Freedman M, Silberfeld M, Krahn M. Utility-based quality of life measures in Alzheimer’s disease. Qual Life Res. 2006;15(4):631–643. doi: 10.1007/s11136-005-4364-8.
    1. Vickrey BG, Mittman BS, Connor KI, Pearson ML, Della Penna RD, Ganiats TG, Demonte RW, Chodosh J, Cui X, Vassar S, Duan N, Lee ML. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Int Med. 2006;145(10):713–726. doi: 10.7326/0003-4819-145-10-200611210-00004.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann. 2002;32:509–521. doi: 10.3928/0048-5713-20020901-06.
    1. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–325. doi: 10.7326/0003-4819-146-5-200703060-00004.
    1. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: Wiley; 1987.
    1. Johannesson M, Jonsson B, Jonsson L, Kobelt G, Zethraeus N. Why Should Economic Evaluations of Medical Innovations have a Societal Perspective? London: Office of Health Economics Briefing No. 51; 2009. .
    1. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996;49(1):95–103. doi: 10.1016/0895-4356(96)89259-6.
    1. Manning W, Fryback DG, Weinstein MC. In: Cost-Effectiveness in Health and Medicine. Gold M, Siegel J, Russell L, Weinstein M, editor. New York: Oxford University Press; 1996. Reflecting uncertainty in cost-effectiveness analysis.
    1. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1–31. doi: 10.1016/S0167-6296(96)00506-1.
    1. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–430. doi: 10.1002/hec.678.
    1. Boustani MA, Jemoumi R, Munger S. Forecasting the future impact of early detection and management Program for Alzheimer disease. Am J Geriatr Psychiatr. 2009;17:A9–A149.
    1. Boustani M, Sachs G, Callahan CM. Can primary care meet the biopsychosocial needs of older adults with dementia? J Gen Intern Med. 2007;22(11):1625–1627. doi: 10.1007/s11606-007-0386-y.
    1. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, Unverzagt F, Hui S, Hendrie HC. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc. 2006;54(1):104–109. doi: 10.1111/j.1532-5415.2005.00543.x.
    1. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Int Med. 1995;122(6):422–429. doi: 10.7326/0003-4819-122-6-199503150-00004.
    1. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):349–361.
    1. Reisberg B, Doody R, Stoffer A, Schmitt F, Ferris S, Möbius HJ. Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341. doi: 10.1056/NEJMoa013128.
    1. Pitkälä KH, Pöysti MM, Laakkonen M, Tilvis RS, Savikko N, Kautiainen H, Strandberg TE. Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial. JAMA Intern Med. 2013;173(10):894–901. doi: 10.1001/jamainternmed.2013.359.
    1. Boustani M, Perkins AJ, Monahan P, Fox C, Watson L, Hopkins J, Fultz B, Hui S, Unverzagt FW, Callahan CM, Hendrie HC. Measuring primary care patients’ attitudes about dementia screening. Int J Geriatr Psychiatry. 2008;23(8):812–820. doi: 10.1002/gps.1983.
    1. Fowler NR, Boustani M, Frame A, Perkins AJ, Monahan P, Gao S, Sachs GA, Hendrie H. Impact of patients’ perceptions on dementia screening in primary care. J Am Geriatr Soc. 2012;60(6):1037–1043. doi: 10.1111/j.1532-5415.2012.03991.x.
    1. Simmons BB, Dejoseph D. Evaluation of suspected dementia. Am Fam Physician. 2011;84(8):895–902.
    1. Reuben D, Roth CP, Frank JC, Hirsch SH, Katz D, McCreath H, Younger J, Murawski M, Edgerly E, Maher J, Maslow K, Wenger NW. Assessing care of vulnerable elders–Alzheimer’s disease: a pilot study of a practice redesign intervention to improve the quality of dementia care. J Am Geriat Soc. 2010;58(2):324–329. doi: 10.1111/j.1532-5415.2009.02678.x.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever